Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

GelTex submits NDA for RenaGel

Nov. 4, 1997

Alza acquires rights to Ditropan

Oct. 24, 1997

Fujisawa describes bradykinin agonists with wide therapeutic application

Oct. 16, 1997

Oral desmopressin evaluated in bed-wetting children

Oct. 13, 1997

Vanguard licenses VML-252 to Sankyo

Oct. 10, 1997

TheraTech joins forces with Meiji and Sankyo to develop and market oxybutynin patch

Oct. 10, 1997

Unique profile described for Glaxo Wellcome's 5alpha-reductase inhibitor

Oct. 8, 1997

Empi's new incontinence device approved by FDA; worldwide launch slated for January

Oct. 7, 1997

Development of YM-46303 stopped

Oct. 2, 1997

Interstim approved for marketing in U.S.

Oct. 1, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...